HUTCHMED (CHINA) LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 283 GBX | -2.41% |
|
-4.07% | 0.00% |
| Jun. 07 | Hutchmed (China) begins trial of menin inhibitor HMPL-506 | AN |
| Jun. 07 | Hutchmed Begins Phase 1 Trial of Potential Treatment for Acute Myeloid Leukemia | MT |
Financials (USD)
| Sales 2024 * | 691M | Sales 2025 * | 849M | Capitalization | 3.07B |
|---|---|---|---|---|---|
| Net income 2024 * | -105M | Net income 2025 * | - | EV / Sales 2024 * | 4.08 x |
| Net cash position 2024 * | 256M | Net cash position 2025 * | 383M | EV / Sales 2025 * | 3.17 x |
| P/E ratio 2024 * |
-28.4
x | P/E ratio 2025 * |
258
x | Employees | 1,988 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on HUTCHMED (China) Limited
More recommendations
More press releases
| 1 day | -2.41% | ||
| 1 week | -4.07% | ||
| Current month | -4.07% | ||
| 1 month | -8.12% | ||
| 3 months | +24.40% | ||
| 6 months | -5.67% |
1 week
279.00
298.00
1 month
279.00353.00
Current year
190.40353.00
1 year
173.60353.00
3 years
130.00656.00
5 years
130.00656.00
10 years
82.50656.00
| Managers | Title | Age | Since |
|---|---|---|---|
Wei Guo Su
CEO | Chief Executive Officer | 66 | 04-12-31 |
Chig Fung Cheng
DFI | Director of Finance/CFO | 57 | 08-06-30 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Graeme Jack
BRD | Director/Board Member | 73 | 17-02-28 |
Dan Eldar
CHM | Chairman | 70 | 16-07-31 |
Edith Shih
BRD | Director/Board Member | 71 | 99-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 283 | -2.41% | 34,721 |
| 24-06-06 | 290 | -0.34% | 98,576 |
| 24-06-05 | 291 | -2.02% | 7,791 |
| 24-06-04 | 297 | +3.12% | 45,201 |
| 24-06-03 | 288 | -2.37% | 44,366 |
Delayed Quote London S.E., June 07, 2024 at 11:35 am EDT
More quotes
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.601
USD
Average target price
5.718
USD
Spread / Average Target
+58.81%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 3.07B | |
| +45.82% | 765B | |
| +40.95% | 632B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| +11.88% | 216B | |
| -0.78% | 219B | |
| +5.90% | 164B |
- Stock Market
- Equities
- HCM Stock
